Cerebras Systems' IPO was highly successful, with shares jumping from an initial $185 to over $300, reflecting strong investor interest in AI chip companies. However, the stock now trades at an expensive valuation of 131.3 times its projected 2025 revenue of $510 million, signaling potential risk for investors. The shares slightly declined by 3.9% the day after the IPO, indicating some market caution despite the initial enthusiasm.
Life360's Board of Directors has approved a multi-year share repurchase program worth up to $225 million to reduce dilution from stock-based compensation. The program aims to return value to shareholders and is supported by the company's strong balan...
President Donald Trump secured a major deal with China, where China agreed to purchase at least $17 billion worth of US agricultural products annually until 2028. This agreement was announced after a two-day summit in China, the first by a US preside...
Former President Donald Trump issued a stern warning to Iran, urging swift action in stalled peace negotiations or face severe consequences. He rejected Iran's demand to separate nuclear talks from peace discussions, emphasizing that time is critical...
Design Therapeutics, a clinical-stage biotech company, will announce data from its ongoing Phase 1/2 RESTORE-FA trial of DT-216P2, a treatment for Friedreich’s ataxia, on May 18, 2026. The company will host a live webcast and conference call to discu...
Novartis announced that combining Pluvicto (lutetium-177 vipivotide tetraxetan) with standard care (ARPI + ADT) significantly improves PSA response in metastatic hormone-sensitive prostate cancer (mHSPC), reducing PSA progression risk by 58% compared...
